Argenx
ARGX
#529
Rank
A$63.11 B
Marketcap
A$1,020
Share price
-1.98%
Change (1 day)
10.61%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2025 (TTM): A$1.48 Billion

According to Argenx 's latest financial reports the company's current earnings are A$3.60 Billion. In 2024 the company made an earning of A$0.11 Billion, an increase over its 2023 earnings that were of -A$0.43 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) A$1.48 B1143.3%
2024 A$0.11 B-127.97%
2023 -A$0.43 Billion-58.25%
2022 -A$1.03 Billion80.17%
2021 -A$0.57 Billion
2019 -A$0.28 Billion124.86%
2018 -A$0.13 Billion131.81%
2017 -A$53.44 Million
2015 -A$25.8 Million
2013 -A$15.61 Million